BMS-986207

BMS-986207 is an investigational, fully human monoclonal antibody that targets the T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an inhibitory checkpoint receptor expressed on various immune cells, including CD8+ T cells, regulatory T cells (Tregs), and Natural Killer (NK) cells. By binding to TIGIT, BMS-986207 blocks its interaction with ligands such as CD155 (PVR) and CD112 (PVRL2), which are frequently overexpressed on tumor cells and antigen-presenting cells. This blockade prevents TIGIT-mediated immunosuppressive signaling, thereby restoring the effector functions of T cells and NK cells and enhancing the anti-tumor immune response. Developed by Bristol Myers Squibb, BMS-986207 is primarily being evaluated in clinical trials for the treatment of advanced solid tumors, often in combination with other immune checkpoint inhibitors such as nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4).

Other names

Anti-TIGIT monoclonal antibody